Your browser doesn't support javascript.
loading
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn, Guy; Wang, Joyce; Purvis, Annie; Ruiz, Martin Sanchez; Adhikarla, Haritha; Alvi, Saad; Bonaparte, Matthew I; Brune, Daniel; Bueso, Agustin; Canter, Richard M; Ceregido, Maria Angeles; Deshmukh, Sachin; Diemert, David; Finn, Adam; Forrat, Remi; Fu, Bo; Gallais, Julie; Griffin, Paul; Grillet, Marie-Helene; Haney, Owen; Henderson, Jeffrey A; Koutsoukos, Marguerite; Launay, Odile; Torres, Federico Martinon; Masotti, Roger; Michael, Nelson L; Park, Juliana; Rivera-Medina, Doris Maribel; Romanyak, Natalya; Rook, Chris; Schuerman, Lode; Sher, Lawrence D; Tavares-Da-Silva, Fernanda; Whittington, Ashley; Chicz, Roman M; Gurunathan, Sanjay; Savarino, Stephen; Sridhar, Saranya.
Afiliação
  • de Bruyn G; Sanofi, Swiftwater, PA, USA.
  • Wang J; Sanofi, Chengdu, China.
  • Purvis A; Sanofi, Waltham, MA, USA.
  • Ruiz MS; Sanofi, Paris, France.
  • Adhikarla H; Sanofi, Swiftwater, PA, USA.
  • Alvi S; Chicago Clinical Research Institute, IL, USA.
  • Bonaparte MI; Sanofi, Swiftwater, PA, USA.
  • Brune D; Optimal Research, Peoria, IL, USA.
  • Bueso A; Demedica, San Pedro Sula, Honduras.
  • Canter RM; Sanofi, Swiftwater, PA, USA.
  • Ceregido MA; GSK, Wavre, Belgium.
  • Deshmukh S; Griffith University, Australia.
  • Diemert D; School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
  • Finn A; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
  • Forrat R; Sanofi, Marcy l'Etoile, France.
  • Fu B; Sanofi, Swiftwater, PA, USA.
  • Gallais J; Sanofi, Marcy l'Etoile, France.
  • Griffin P; Mater Health, Brisbane, Queensland, Australia.
  • Grillet MH; The University of Queensland, Brisbane, Queensland, Australia.
  • Haney O; Sanofi, Lyon, France.
  • Henderson JA; Sanofi, Swiftwater, PA, USA.
  • Koutsoukos M; Black Hills Center for American Indian Health, SD, USA.
  • Launay O; GSK, Wavre, Belgium.
  • Torres FM; Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • Masotti R; Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain.
  • Michael NL; Genetics, Vaccines- Infectious Diseases and Pediatrics Research Group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
  • Park J; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Rivera-Medina DM; Sanofi, Swiftwater, PA, USA.
  • Romanyak N; Walter Reed Army Institute of Research, Silver Spring, MD, USA.
  • Rook C; Sanofi, Sydney, Australia.
  • Schuerman L; INVERIME S.A, Tegucigalpa, Honduras.
  • Sher LD; Sanofi, Swiftwater, PA, USA.
  • Tavares-Da-Silva F; Cmax, Adelaide, Australia.
  • Whittington A; GSK, Wavre, Belgium.
  • Chicz RM; Peninsula Research Associates, Rolling Hills Estates, CA, USA.
  • Gurunathan S; GSK, Wavre, Belgium.
  • Savarino S; London North West University Healthcare NHS Trust, London, UK.
  • Sridhar S; Sanofi, Waltham, MA, USA.
EClinicalMedicine ; 62: 102109, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37533419
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article